{"entity":{"id":"nct06840119","kind":"trial","name":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","aka":[],"tldr":"A phase 1/2 trial of IMC-R117C in advanced solid tumours, run by Immunocore Ltd, now recruiting.","summary":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers is a phase 1/2 interventional study registered as NCT06840119 by Immunocore Ltd, with 600 participants planned, started 2024-01-10 and due to reach its primary completion in 2026-11-30. Interventions recorded: IMC-R117C, Chemotherapy drug, Kinase inhibitor, Antiangiogenic Agent and Monoclonal antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06840119","url":"https://clinicaltrials.gov/study/NCT06840119"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["immunocore"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06840119","phase":"1/2","setting":"A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers","sponsor":"Immunocore Ltd","enrolled":600,"outcomes":[]},"route":"/trials/nct06840119/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"immunocore","kind":"company","name":"Immunocore","route":"/companies/immunocore/"}]}}